HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ness, J. M. Search for Related Content PubMed PubMed Citation Articles by Ness, J. M.

Clinical features of children and adolescents with multiple sclerosis

From the Department of Pediatrics (J.M.N.), University of Alabama at Birmingham and Children's Hospital; Multiple Sclerosis Center at UCSF (D.C.), University of California, San Francisco; Department of Medical Genetics and Faculty of Medicine (A.D.S.), Division of Neurology, University of British Columbia, Vancouver, Canada; Department of Pediatrics and Pediatric Neurology (D.P.), Georg-August-University Goettingen, Germany; Department of Pediatrics (Neurology) (B.B.), The Hospital for Sick Children, Toronto, Canada; and Baird MS Center (B.W.-G.), Jacobs Neurological Institute, Buffalo, NY.

Address correspondence and reprint requests to Dr. Jayne Ness, Children's Hospital of Alabama, 1600 7th Avenue South, CHB 314, Birmingham, AL 35233-1711; e-mail: jness{at}peds.uab.edu.

There is increasing appreciation that multiple sclerosis (MS) can begin in childhood or adolescence, but pediatric MS continues to be a rare entity, with an estimated 2 to 5% of patients with MS experiencing their first clinical symptoms before age 16. A prompt diagnosis of pediatric MS is important to optimize overall management of both the physical and social impact of the disease. The widespread use of disease-modifying therapies (DMT) for MS in adults, as early as following an initial isolated episode, has led to the use of DMT in children and adolescents with MS. However, it is imperative to distinguish pediatric MS from other childhood CNS inflammatory demyelinating disorders such as acute disseminated encephalomyelitis. Although increasing evidence suggests a slower disease course in children with MS compared to adults, significant disability can still accumulate by early adulthood. Furthermore, associated neurocognitive deficits can impair both academic and psychosocial function at a critical juncture in a young person's life. This article reviews the clinical characteristics, neuroimaging, paraclinical findings, disease course, epidemiology, genetics, and pathophysiology of pediatric MS vis-à-vis adult MS. Further research of pediatric MS may advance our understanding of MS pathophysiology in general, as well as improve the long-term health care outcomes of children and adolescents diagnosed with MS.

*Members of the International Pediatric MS Study Group are listed in the Appendix.

Disclosure: The authors report no conflicts of interest.

This article has been cited by other articles:

				B. L. Banwell Through the eyes of a child: research insights gained through the study of childhood multiple sclerosis Multiple Sclerosis, January 1, 2008; 14(1): 4 - 5. [PDF]